# Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

> **NCT01257399** · PHASE3 · COMPLETED · sponsor: **Tillotts Pharma AG** · enrollment: 251 (actual)

## Conditions studied

- Ulcerative Colitis in Remission

## Interventions

- **DRUG:** Asacol®
- **DRUG:** Mesalazine

## Key facts

- **NCT ID:** NCT01257399
- **Lead sponsor:** Tillotts Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2013-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257399, "Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01257399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*